Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

What T cells see in WT-1.

Molldrem JJ.

Blood. 2012 Aug 23;120(8):1540-1. doi: 10.1182/blood-2012-06-433979.

2.

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ.

Blood. 2012 Aug 23;120(8):1633-46. doi: 10.1182/blood-2011-11-394619. Epub 2012 May 23.

3.

Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. Erratum in: Clin Cancer Res. 2007 Sep 1;13(17):5226.

4.

Defining MHC class II T helper epitopes for WT1 tumor antigen.

Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E.

Cancer Immunol Immunother. 2006 Jul;55(7):850-60. Epub 2005 Oct 12.

PMID:
16220325
5.

Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.

Asemissen AM, Keilholz U, Tenzer S, Müller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C.

Clin Cancer Res. 2006 Dec 15;12(24):7476-82.

6.

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.

Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H.

Immunogenetics. 2000 Feb;51(2):99-107.

PMID:
10663572
7.

Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.

Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H.

J Immunother. 2007 Apr;30(3):282-93.

PMID:
17414319
8.

Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.

Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H.

Microbiol Immunol. 2008 Nov;52(11):551-8. doi: 10.1111/j.1348-0421.2008.00069.x.

9.

Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes.

Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M.

Br J Haematol. 2002 Mar;116(3):601-3.

PMID:
11849218
10.

Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner.

Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I, Hato T, Takahashi M, Senju S, Nishimura Y, Yasukawa M.

Blood. 2005 Aug 15;106(4):1415-8. Epub 2005 Apr 21.

11.

WT1-targeted immunotherapy of leukaemia.

Xue S, Gao L, Gillmore R, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Stauss HJ, Morris E.

Blood Cells Mol Dis. 2004 Nov-Dec;33(3):288-90.

PMID:
15528146
12.

[Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].

Gu WY, Cao XS, Qiu GQ, Chen ZX, Sheng LX, Xie XB, He J, Cen JN, Shen HL.

Zhonghua Yi Xue Za Zhi. 2005 Dec 28;85(49):3475-80. Chinese.

PMID:
16686063
13.

Identification of a Wilms' tumor 1-derived immunogenic CD4(+) T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes.

Anguille S, Fujiki F, Smits EL, Oji Y, Lion E, Oka Y, Berneman ZN, Sugiyama H.

Leukemia. 2013 Mar;27(3):748-50. doi: 10.1038/leu.2012.248. Epub 2012 Aug 29. No abstract available.

PMID:
22929521
14.

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.

Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ.

Blood. 2002 Nov 15;100(10):3835-7.

15.

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ.

Blood. 2009 Mar 5;113(10):2245-55. doi: 10.1182/blood-2008-03-144071. Epub 2008 Nov 6.

16.

Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.

Al Qudaihi G, Lehe C, Negash M, Al-Alwan M, Ghebeh H, Mohamed SY, Saleh AJ, Al-Humaidan H, Tbakhi A, Dickinson A, Aljurf M, Dermime S.

Leuk Lymphoma. 2009 Feb;50(2):260-9. doi: 10.1080/10428190802578478.

PMID:
19197722
17.

Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.

Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S.

J Immunol. 2005 Jun 15;174(12):8210-8.

18.

WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.

Li Z, Oka Y, Tsuboi A, Masuda T, Tatsumi N, Kawakami M, Fujioka T, Sakaguchi N, Nakajima H, Fujiki F, Udaka K, Oji Y, Kawase I, Sugiyama H.

Int J Hematol. 2005 Dec;82(5):458-9. No abstract available.

PMID:
16533753
19.

Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.

Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P.

J Immunol. 1999 Sep 1;163(5):2928-36.

20.

Cancer immunotherapy targeting WT1 protein.

Sugiyama H.

Int J Hematol. 2002 Aug;76(2):127-32. Review.

PMID:
12215010

Supplemental Content

Support Center